Correlative Study Between Serum Matrix Metalloproteinase 9 Values and Neurologic Deficit in Acute, Primary, Supratentorial, Intracerebral Haemorrhage

Open access


One of the essential characteristics of intracerebral haemorrhages (ICH) is the occurrence of brain oedema (BE). Matrix metalloproteinase-9 (MMP-9) belongs to the family of proteolytic enzymes connected with zinc, which in brain bleeding or a stroke can induce matrix proteolyse into the neurovascular unit, and increase the BE. The aim of the study was to determine the MMP-9 values in serum, and to assess the degree of correlation with neurological deficit in patients with acute, primary and supratentorial ICH.

Materials: The study was prospective and included 62 patients with ICH. The neurological deficit of the patients was evaluated by the National Institute Health Stroke Scale (NIHSS). Serum MMP-9 level was determined by enzyme-linked immune sorbent assay (ELISA). Patients were evaluated in three phases: 1st, 3rdand 7th day following the ICH.

Results: The mean age of the patients was 64.5 ± 9.4. Within the follow-up period, there was a significant rise of the NIHSS score in the first three days: 11.48 ± 3.7; 13.21 ± 3.78, and a significant rise of serum MMP-9, with greatest values in the third day: 134.7 ± 26.1 ng/ml (p = 0.000). There was a positive, significant correlation (r = 0.886, p = 0.000) between the serum MMP-9 concentration and the NIHSS score.

Conclusion: Our study showed that in the first three days of ICH, serum MMP-9 values were rising as well as the neurological deficit and the BE. Determination and evaluation of the MMP-9 in serum is an easy, non-invasive, routine laboratory procedure for the detection and follow-up of BE, and also determines further therapeutic strategy as well as prognosis in these patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Adams DR Victor M. Principles of Neurology. New York Mc Graw-Hill Inc 1993.

  • 2. Skidmore CT Andrefsky J. Spontaneous intracerebral hemorrhage: epidemiology patophysiology and medical menagement. Neurosurg Clin N Am. 2002; 13: 281–288.

  • 3. Bahemuka M Primary intracerebral hemorrhagy and heart weight: a clinicopathological case control re view of 218 patients. Stroke. 1987; 18: 531–536.

  • 4. Huang FP Xi G Keep RF et al. Brain edema after experimental intracerebral hemorrage; Role of hemglobin degradation products. J Neurosurg. 2002; 96: 287–293.

  • 5. Nagase H. Activation mechanisms of matrix metaloproteinases. Biol Chem. 1997; 378: 151–160.

  • 6. Rosenberg G Navratil M. Metalloproteinase inhbition blocks edema in intracerebral hemorrhage in the rat. Neurology. 1997; 48: 921–926.

  • 7. Lapchak P Chapman D Zivin J. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000; 31: 3034–40.

  • 8. Pfefferkorn T Rosenberg G. Closure of the blood– brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003; 34: 2025–30.

  • 9. Alvarez-Sabin J Delgado P Abilleira S Molina C Arenillas J Ribo M et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontneous intracerebral hemorrhage: relationship to clincal and radiological outcome. Stroke. 2004; 35: 1316–22.

  • 10. Abilleira S Montaner J Molin C et al. Matrix metaloproteinase-9 contretation after spontaneous intracrebral hemorrhage. J Neurosurg. 2003; 99: 65–70.

  • 11. De Graba JT Hallenbeck MJ Pettigrew DK et al. Progresion in acute stroke: Value of the initial NIH stroke scale score on patients stratification in future trials. Stroke. 1999; 30: 1208–1212.

  • 12. Baird AE Dasche J Connor A et al. Comparision of retrospective and prospecive measurements of the national institutes of health stroke scale. Cerebrovasc Dis. 2000; 10: 80–81.

  • 14. Adams H. Handbook of cerebrovascular disease. New York: Dekker; 1996

  • 15. Abilleira S Montaner J Molin C et al. Matrix metalloproteinase-9 contretation after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99: 65–70.

  • 16. Leira R Davalos A Silva Y et al. Stroke Project Cerebrovascularis Diseases Group of Spanish Neu rological Society. Early neurological deterioration in intracerebral hemorrage: predictors and associated factors. Neurology. 2004; 63: 461–467.

  • 17. Tejima E Guo S Murata Y et al. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma. 2009; 26(11): 1935–1941.

  • 18. Mahajan SD Aalinkeel R Reynolds JL et al. Suppression of MMP-9 expression in brain micro-vascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest. 2012; 41(4): 337–355.

Journal information
Impact Factor
CiteScore 2017: 0.45

SCImago Journal Rank (SJR) 2018: 0.177

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 336 263 8
PDF Downloads 248 222 2